Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Edwards Lifesciences Corp

Get SEC filing alerts via email and in your feed for Edwards Lifesciences Corp

EW

Edwards Lifesciences Corp

About Edwards Lifesciences Corp

Edwards Lifesciences is a global leader in structural heart disease solutions, specializing in innovative surgical and transcatheter therapies for valve repair and replacement. Its core products include transcatheter aortic valves, mitral and tricuspid repair systems, and surgical tissue valves. Serving patients worldwide, the company emphasizes clinical evidence, product innovation, and partnerships to improve outcomes and address the growing burden of cardiovascular disease.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Edwards Lifesciences Corp

1
1
Edwards Lifesciences Corp Edwards Lifesciences Reports 16.7% Revenue Growth to $1.65 Billion in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Edwards Lifesciences Corp Edwards Lifesciences Reports $6.1 Billion in Net Sales for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Edwards Lifesciences Corp Edwards Lifesciences Reports 14.7% Revenue Growth to $1.55 Billion in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Edwards Lifesciences Corp Edwards Lifesciences Reports 11.9% Net Sales Increase to $1.53 Billion in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Edwards Lifesciences Corp Edwards Lifesciences Reports 6.2% Net Sales Increase to $1.413 Billion in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Edwards Lifesciences Corp Edwards Lifesciences Reports 8.6% Net Sales Increase to $5.4 Billion for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Edwards Lifesciences Corp Edwards Lifesciences Reports Strong Financial Growth in Q3 and Nine Months of 2024

Via official filing (AI summary) | over 1 year ago | 0 comments